Impact of COVID-19 on Patients With Psoriasis or Psoriatic Arthritis.
Where this comes from
- Record sourced from PubMed, PMID 37527863.
- Also identified by DOI 10.3899/jrheum.2023-0521.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Given the impact of the coronavirus disease 2019 (COVID-19) on patients with psoriatic disease (PsD), a session was devoted at the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2022 annual meeting to discussing the current understanding of the risk of severe COVID-19 in patients with PsD. The effects of PsD and its treatment on prevention and treatment of COVID-19 with vaccinations, antiviral drugs, and monoclonal antibodies were discussed. The session concluded with a presentation on the perspectives of patient research partners about their experiences with COVID-19.
Medical subject headings
- Arthritis, Psoriatic
- Rheumatology
- Dermatology
- COVID-19
- Psoriasis